Hady Ghanem, MD

Clinical Associate Professor
Division of Hematology-Oncology

Division Head, Hematology-Oncology

Dr. Ghanem is an American Board-Certified Physician in Internal Medicine, Hematology, and Oncology. He currently serves as the Chief of the Hematology-Oncology Division at the Lebanese American University Medical Center – Rizk Hospital (LAUMC-RH). Dr. Ghanem earned his Medical Degree (MD) from the Faculty of Medicine at Saint Joseph University in Beirut.

He completed his Internal Medicine residency at Cooper University Hospital in New Jersey, USA, followed by a 3-year fellowship in Hematology-Oncology at George Washington University Hospital in Washington, DC. He further specialized by completing a sub-specialty fellowship in Leukemia at MD Anderson Cancer Center in Houston, Texas.

Dr. Ghanem is an Associate Professor at the Lebanese American University and is actively involved in teaching medical students and residents. He is the founder and former director of the Hematology-Oncology Fellowship Program at LAUMC-RH. Throughout his career, he has received numerous awards for outstanding clinical achievements and has authored over 40 papers and book chapters.

In addition to his academic and clinical roles, Dr. Ghanem is a member of the Alpha Omega Alpha (AOA) Honor Medical Society and is actively involved in several committees related to patient care, ethics, and patient satisfaction. He also chairs the Pharmacy and Therapeutics Committee at LAUMC-RH and serves on the Ministry of Health committee for oncology drug approvals. Dr. Ghanem frequently lectures nationally and internationally at oncology seminars and symposia, contributing his expertise to the field.

Selected Publications

1. Kattan J, Temraz S, Nasr F, Tfayli AH, Khater C, Mugharbel A, Ghanem H, Kourie HR, Hachem G, Masri S, Debs J, Shamseddine A. (2024). Management Practices of Locally Advanced and Metastatic Urothelial Carcinoma: A Questionnaire-Based Survey among Lebanese Oncologists.  Open Journal of Urology. (2024) 14:138-149, ISSN Online: 2160-5629
2. Ghosn M, Kattan J, Karak FE, Ghanem H, Debs J, Ibrahim K, Shamseddine A. Renal cell carcinoma management: real-world practice and challenges at a national level. Future Oncol. (2023 Apr) 19(12):863-872.
3. Abdallah R, Atallah D, Bitar N, Chahine G, Ghanem H, Ghosn M, Kattan J, Nasr F, Makdessi J, Shamseddine A. Consensus on the management of platinum-sensitive high-grade serous epithelial ovarian cancer in Lebanon. Gynecol Oncol Rep. (2023 Apr) 47:101186.
4. Hamadeh LN, Farhat L, Hilal L, Assi H, Nasr F, Chahine G, Kattan J, Farhat F, Kourie H, El Hachem G, Ghosn M, El Saghir N, Chamseddine N, Finianos A, Ghanem H, Younes A, Gerges DA, Temraz S, Haidar M, Nabhan T, Chamseddine A, Tfayli A, Zaatari G, Mahfouz R. Frequency and mutational spectrum of PIK3CA gene mutations in breast cancer patients: Largest and first report from Lebanon. Gene. (2023 Apr) 871:147433.
5. Chedid G, Khoury R, Noureldine HA, Gerges Harb J, Tannoury E, Semaan S, Elias-Rizk T, Ghanem, H. Hepatic Vein Thrombosis in a COVID-19 Patient with Hereditary Thrombophilia: A Case Report. International Journal of Clinical Research. (2022) 3(1):127-131.
6. El Saghir NS, Ghanem H, El Karak F, Farhat F, Ghosn M, Makdessi J, Chouaib K, Debs J, Tabchy AB. Management of breast cancer patients with BRCA gene mutations in Lebanon of the Middle East: perspectives and challenges. Hosp Pract (1995). (2021 Dec) 49(5):325-329.
7. Nader R, Tannoury E, Rizk T, Ghanem H. Atezolizumab-induced encephalitis in a patient with metastatic breast cancer: a case report and review of neurological adverse events associated with checkpoint inhibitors. Autops Case Rep. (2021 Apr) 11:e2021261.
8. Assi R, Masri N, Dalle IA, El-Cheikh J, Ghanem H, Bazarbachi A. Polatuzumab Vedotin: Current Role and Future Applications in the Treatment of Patients with Diffuse Large B-Cell Lymphoma. Clin Hematol Int. (2021 Mar) 3(1):21-26.

Professional and Research Interests

• Research and teaching
• Leukemia
• Lymphoma
• Lung cancer
• Breast cancer
• Focus on molecular targets and immunotherapy

Education and Training

• M.D. Degree, Faculty of Medicine,  Saint Joseph University, Beirut, Lebanon 2005
• M.D. Certificate, Educational Committee for Foreign Medical Graduates, Philadelphia, PA, U.S.A 2006
• Residency in Internal Medicine, Cooper university hospital -University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Camden, New Jersey, U.S.A 2009
• Fellowship in Hematology and Oncology, George Washington University Hospital, Washington DC, U.S.A 2012
• Fellowship in Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas, U.S.A 2013

Professional Memberships and Organizations

• American board of internal medicine, August 2009.
• American board of Hematology (October 2012), ongoing recertification (LKA)
• American board of Oncology (October 2012), ongoing recertification (LKA)
• Alpha Omega Alpha (AOA), medical honor society
• American College of Physicians
• American Society of Clinical Oncology (ASCO)
• American Society of Hematology (ASH)
• Lebanese Society of Medical Oncology (LSMO)

Keywords

Hematology, oncology, cancer, leukemia, lymphoma, myeloma, immunotherapy, molecular genetics, benign hematology, thrombophilia, bleeding disorders, hematologic malignancy, bone marrow disorder, hematologic disease, thalassemia, sickle cell disease, anemia